In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.

Considering that HF is constantly increasing in prevalence, it can be expected that the number of NT-proBNP assays will increase to meet the growing demand in HF diagnostics. In particular, the introduction of point-of-care-testing assays may contribute to assay variability.